BG
GPCR icon

Bellevue Group’s Structure Therapeutics GPCR Stock Holding History

Bellevue Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Sell
4,762
-2,041
-30% -$90.3K 0.01% 122
2026
Q1 		$328K Sell
6,803
-138,364
-95% -$9.47M 0.01% 120
2025
Q4 		$10.1M Sell
145,167
-170,690
-54% -$6.97M 0.19% 62
2025
Q3 		$8.84M Sell
315,857
-32,670
-9% -$651K 0.18% 63
2025
Q2 		$7.23M Buy
348,527
+126,812
+57% +$2.79M 0.16% 72
2025
Q1 		$3.84M Sell
221,715
-263,335
-54% -$6.45M 0.09% 92
2024
Q4 		$13.2M Sell
485,050
-144,708
-23% -$5.13M 0.25% 73
2024
Q3 		$27.6M Buy
629,758
+72,437
+13% +$2.8M 0.45% 65
2024
Q2 		$21.9M Buy
557,321
+193,395
+53% +$7.94M 0.36% 69
2024
Q1 		$15.6M Buy
363,926
+351,626
+2,859% +$14.8M 0.24% 86
2023
Q4 		$501K Sell
12,300
-4,500
-27% -$258K 0.01% 135
2023
Q3 		$847K Buy
+16,800
New +$541K 0.01% 134

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bellevue Group's GPCR Position: Q2 2026 in Review

Bellevue Group reduced its Structure Therapeutics (GPCR) stake by 30% in Q2 2026, selling an estimated $90.3K and leaving 4,762 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #122.

Bellevue Group first reported a position in GPCR in Q3 2023 and has held it in 12 quarters since. The position peaked at $27.6M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Bellevue Group held 4,762 shares of Structure Therapeutics worth $256K as of Q2 2026.
  • Bellevue Group sold 2,041 Structure Therapeutics shares in Q2 2026, an estimated $90.3K.
  • Structure Therapeutics made up 0.01% of Bellevue Group's portfolio in Q2 2026, its #122 holding.
  • Bellevue Group first reported a position in Structure Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Bellevue Group's Structure Therapeutics position peaked at $27.6M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.